Paclitaxel-eluting stents for the treatment of complex coronary lesions: Immediate and 12-month results

Journal of Cardiovascular Medicine

Volumn 8, Issue 8, 2007, Pages 582-588

  Sheiban, Imad ^a   Ballari, Gian Paolo ^a   Moretti, Claudio ^a   Marra, Walter Grosso ^a   Meliga, Emanuele ^a   Omedè, Pierluigi ^a   Sciuto, Filippo ^a   Trevi, Gian Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Coronary angioplasty; Coronary artery disease; Coronary restenosis; Drug eluting stents; Paclitaxel eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; TICLOPIDINE;

ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST ELEVATION MYOCARDIAL INFARCTION; PATIENT SAFETY; ST ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STROKE; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; ODDS RATIO; PACLITAXEL; PROSTHESIS DESIGN; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547655847     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000281708.66552.02     Document Type: Article

References (31)

1. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993; 21:15-25.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489-495.
3. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993; 329:221-227.
4. Baim DS, Cutlip DE, Sharma SK, Ho KK, Fortuna R, Schreiber TL, et al. Final results of the Balloon vs. Optimal Atherectomy Trial (BOAT). Circulation 1998; 97:322-331.
5. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082-2089.
6. Mehran R, Mintz GS, Satler LF, Pichard AD, Kent KM, Bucher TA, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation 1997; 96:2183-2189.
7. Koster R, Hamm CW, Seabra-Gomes R, Herrmann G, Sievert H, Macaya C, et al. Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators. J Am Coll Cardiol 1999; 34:25-32.
8. Albiero R, Silber S, Di Mario C, Cernigliaro C, Battaglia S, Reimers B, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the Restenosis Cutting Balloon Evaluation Trial (RESCUT). J Am Coll Cardiol 2004; 43:943-949.
9. Adamian M, Colombo A, Briguori C, Nishida T, Marsico F, Di Mario C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol 2001; 38:672-679.
10. Bhargava B, Karthikeyan G, Abizaid AS, Mehran R. New approaches to preventing restenosis. BMJ 2003; 327:274-279.
11. Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med 2001; 344:243-249.
12. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344:250-256.
13. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 2002; 359:551-557.
14. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part I. Circulation 2002; 106:2734-2740.
15. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352:673-681.
16. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al., for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
17. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104:2007-2011.
18. Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, Moshiri S, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002; 105:1883- 1886.
19. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348:1537-1545.
20. Gershlick AH, Descheerder I, Chevalier B, Camenzind E, Gommeaux A, Vrints C, et al. Local drug delivery to inhibit coronary artery restenosis. Data from the ELUTES (Evaluation of Paclitaxel Eluting Stent) clinical trial [abstract]. Circulation 2001; 104:II416.
21. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107:38-42.
22. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, et al., for the TAXUS II Study Group. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents. Comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004; 109:196-200.
23. Serruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb J, et al., for the TAXUS II Study Group. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004; 109:627-633.
24. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, et al., for the TAXUS II Study Group. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 2005; 111:900-905.
25. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107:559-564.
26. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al., for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
27. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al., for the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109:1942-1947.
28. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al., for the TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005; 112:3306-3313.
29. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al., for the TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005; 45:1172-1179.
30. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al., for the ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353:663-670.
31. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 2005; 45:1180-1185.